Stereotaxis, Inc. Form 8-K Summary
Business Context and Reporting Period
Company: Stereotaxis, Inc. (STXS)
Filing Date: April 14, 2026
Reporting Period: Current Report (Event Date: April 14, 2026)
Business Context: Stereotaxis, a developer of robotic technology for interventional cardiology, announced the entry into a definitive agreement to acquire 100% of Robocath, a French venture-backed innovator in mechanical robotic technology for interventional cardiology and neurointerventions.
Key Financial Metrics and Transaction Terms
This filing details a material definitive agreement rather than periodic financial results. Key transaction metrics include:
- Upfront Consideration: $20.0 million (cash, stock valued at $2.00/share, or combination), subject to adjustments for indebtedness, working capital, and interim financing.
- Contingent Earnout: Up to $25.0 million total.
- $10.0 million for regulatory milestones (US FDA approval).
- Up to $15.0 million for commercial milestones ($5.0 million and $10.0 million based on sales targets).
- Interim Financing: Stereotaxis agreed to provide monthly bonds (IF Bonds) to Robocath totaling approximately €1.3 million until closing.
- Equity Cap: Total shares issuable (upfront + earnout) capped at 19.9% of pre-closing outstanding shares to avoid shareholder approval under NYSE American rules.
- Termination Fee: Greater of 10% of total consideration in an alternative transaction or $5.0 million.
Note: The filing does not provide Stereotaxis's current revenue, profit, cash flow, or debt levels. These figures are not disclosed in this 8-K.
Material Changes and Conditions
The acquisition represents a strategic expansion into neurointerventions and advanced mechanical robotics. The transaction is subject to several closing conditions:
- Completion of debt restructuring by Stereotaxis and its lenders.
- Regulatory clearance from French authorities (Direction Générale du Trésor).
- Absence of legal injunctions or material adverse effects on Robocath.
- Accuracy of representations and warranties.
Expected Closing: July 2026.
End Date: December 31, 2026.
Guidance, Outlook, and Risks
Management Commentary: The company views Robocath as a strategic fit to enhance its portfolio in interventional cardiology and neurointerventions. The deal structure includes pre-funded warrants for certain sellers to manage equity dilution.
Risks and Contingencies:
- Regulatory Risk: Failure to obtain French regulatory clearance or US FDA approvals required for earnouts.
- Integration Risk: Challenges in integrating Robocath's operations and retaining key personnel.
- Financial Risk: Requirement to restructure existing debt prior to closing; potential for unexpected costs.
- Forward-Looking Statements: Actual results may differ due to uncertainties in transaction timing, milestone achievement, and market conditions.
Investor Verification Checklist
- Verify the status of Stereotaxis's required debt restructuring transactions.
- Confirm the timeline for French regulatory clearance (Direction Générale du Trésor).
- Review the specific definitions of the regulatory and commercial milestones triggering the $25 million earnout.
- Assess the impact of the 19.9% equity cap on the final share count and potential dilution.
- Monitor the interim financing drawdowns (IF Bonds) and their impact on Stereotaxis's liquidity prior to closing.